MiMedx Group, Inc. (MDXG)
| Market Cap | 1.10B |
| Revenue (ttm) | 393.44M |
| Net Income (ttm) | 40.83M |
| Shares Out | 148.10M |
| EPS (ttm) | 0.27 |
| PE Ratio | 27.55 |
| Forward PE | 21.97 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 880,995 |
| Open | 7.33 |
| Previous Close | 7.33 |
| Day's Range | 7.23 - 7.47 |
| 52-Week Range | 5.79 - 10.14 |
| Beta | 1.63 |
| Analysts | Buy |
| Price Target | 12.00 (+61.29%) |
| Earnings Date | Oct 29, 2025 |
About MDXG
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The co... [Read more]
Financial Performance
In 2024, MiMedx Group's revenue was $348.88 million, an increase of 8.52% compared to the previous year's $321.48 million. Earnings were $42.42 million, a decrease of -8.94%.
Financial StatementsAnalyst Summary
According to one analyst, the rating for MDXG stock is "Buy" and the 12-month stock price target is $12.0.
News
MiMedx: Breakout Setup Into A Policy Overhaul
MiMedx Group is positioned for growth, with strong earnings, record Q3 revenue, and a rising contribution from its Surgical business. MDXG is proactively managing 2026 reimbursement policy risks by sh...
MIMEDX Comments on CY 2026 Medicare Physician Fee Schedule Final Rule
MARIETTA, Ga., Nov. 03, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today commented on the Centers for Medicare and Medicaid Services (“CMS”) release of the ...
MiMedx Group, Inc. (MDXG) Q3 2025 Earnings Call Transcript
MiMedx Group, Inc. ( MDXG) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Matthew Notarianni - Head of Investor Relations Joseph Capper - CEO & Director Douglas Rice - Chief ...
MIMEDX Announces Record Revenue for Third Quarter 2025
Second Consecutive Quarter of Highest Quarterly Net Sales in MIMEDX History Third Quarter Net Sales of $114 million Grew 35% Year-Over-Year Third Quarter GAAP Net Income and Diluted Earnings Per Shar...
MIMEDX to Host Third Quarter 2025 Operating and Financial Results Conference Call on October 29
MARIETTA, Ga., Oct. 15, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third qua...
MIMEDX Announces Launch of EPIXPRESS®
Next-Generation, Lyophilized Human Placental Allograft Further Expands Company's Broad Portfolio of Advanced Wound Care (“AWC”) Products Next-Generation, Lyophilized Human Placental Allograft Further ...
MIMEDX to Sponsor and Attend Symposium on Advanced Wound Care (SAWC) Fall
To Present Six Posters Featuring the Company's Latest Product Innovations To Present Six Posters Featuring the Company's Latest Product Innovations
MIMEDX to Participate in Upcoming Investor Conferences
MARIETTA, Ga., Aug. 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following i...
MiMedx Group, Inc. (MDXG) Q2 2025 Earnings Call Transcript
MiMedx Group, Inc. (NASDAQ:MDXG) Q2 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants Douglas C. Rice - Chief Financial Officer Joseph H.
MIMEDX Announces Record Second Quarter 2025 Operating and Financial Results
Highest Quarterly Net Sales in MIMEDX History Second Quarter Net Sales of $99 million Grew 13% Year-Over-Year Second Quarter GAAP Net Income and Diluted Earnings Per Share were $10 Million and $0.06,...
MIMEDX Announces Strategic Collaboration with Vaporox, Inc.
MARIETTA, Ga., July 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) and Vaporox, Inc. (“Vaporox”) today jointly announced a collaboration, whereby the compan...
MIMEDX to Host Second Quarter 2025 Operating and Financial Results Conference Call on July 30
MARIETTA, Ga., July 16, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second qu...
MIMEDX Comments on Proposed Medicare Reimbursement Rule Changes for CY 2026
New Mechanism for the Reimbursement of Skin Substitutes Aimed at Curbing Fraud, Waste and Abuse New Mechanism for the Reimbursement of Skin Substitutes Aimed at Curbing Fraud, Waste and Abuse
MIMEDX to Present at the BofA Securities 2025 Healthcare Conference
MARIETTA, Ga., May 06, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the BofA Securit...
MIMEDX Announces Publication of Health Economics Data in Mohs Micrographic Surgery (MMS)
Propensity Score-Matched, Comparative Cost-Effectiveness Analysis of the Company's EPIFIX® Placental Allograft Product Propensity Score-Matched, Comparative Cost-Effectiveness Analysis of the Company'...
MiMedx Group, Inc. (MDXG) Q1 2025 Earnings Call Transcript
MiMedx Group, Inc. (NASDAQ:MDXG) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Matthew Notarianni - Head, IR Joseph Capper - CEO & Director Doug Rice - CFO Conferenc...
MIMEDX Announces First Quarter 2025 Operating and Financial Results
Net Sales of $88 million Grew 4% Year-Over-Year for the First Quarter First Quarter GAAP Net Income and Earnings Per Share were $7 Million and $0.05, Respectively First Quarter Adjusted EBITDA was $17...
MIMEDX to Feature Growing Body of Clinical and Scientific Evidence at Upcoming Wound & Surgical-Focused Industry Conferences
MARIETTA, Ga., April 10, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will participate in the following industry conferences this quar...
MIMEDX to Present at TD Cowen 45th Annual Health Care Conference
MARIETTA, Ga., Feb. 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that senior management will participate in the TD Cowen 45th Annual Healt...
MiMedx Group, Inc. (MDXG) Q4 2024 Earnings Call Transcript
MiMedx Group, Inc. (NASDAQ:MDXG) Q4 2024 Earnings Conference Call February 26, 2024 4:30 AM ET Company Participants Matt Notarianni - Head, Investor Relations Joseph Capper - Chief Executive Officer ...
MIMEDX Announces Fourth Quarter and Full Year 2024 Operating and Financial Results
Net Sales Grew 7% Year-Over-Year for the Fourth Quarter and 9% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $7 million and $0.05, Respectively Fourth Quarter Adjusted E...
MIMEDX's Advocacy to Rein in Runaway Medicare Spend for Skin Substitutes Has Yielded Significant Results with Planned Implementation of LCDs
Over 200 Unproven Skin Substitutes Will No Longer Be Covered Under Revised LCDs Company to Benefit from MACs' Commitment to Clinically Effective, Proven Products MARIETTA, Ga., Nov. 14, 2024 (GLOBE NE...
MiMedx Group, Inc. (MDXG) Q3 2024 Earnings Call Transcript
MiMedx Group, Inc. (NASDAQ:MDXG) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Matt Notarianni - Head, Investor Relations Joe Capper - Chief Executive Officer Doug...
MIMEDX Announces Third Quarter 2024 Operating and Financial Results
Net Sales of $84 million Grew 3% Year-Over-Year for the Third Quarter Third Quarter GAAP Net Income and Earnings Per Share were $8 Million and $0.05 , Respectively Third Quarter Adjusted EBITDA was $1...
MIMEDX to Host Third Quarter 2024 Operating and Financial Results Conference Call on October 30
MARIETTA, Ga., Oct. 14, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third qua...